Research ExplorerPublicationsEffect of secukinumab on quality of life and psoriasis-relat...

Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study

Standard

Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. / Puig, Lluís; Augustin, Matthias; Blauvelt, Andrew; Gottlieb, Alice B; Vender, Ron; Korman, Neil J; Thaçi, Diamant; Zhao, Yang; Gilloteau, Isabelle; Sherif, Bintu; Williams, Nicole; Guana, Adriana; Lebwohl, Mark G.

In: J AM ACAD DERMATOL, Vol. 78, No. 4, 04.2018, p. 741-748.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Puig, L, Augustin, M, Blauvelt, A, Gottlieb, AB, Vender, R, Korman, NJ, Thaçi, D, Zhao, Y, Gilloteau, I, Sherif, B, Williams, N, Guana, A & Lebwohl, MG 2018, 'Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study', J AM ACAD DERMATOL, vol. 78, no. 4, pp. 741-748. https://doi.org/10.1016/j.jaad.2017.10.025

APA

Puig, L., Augustin, M., Blauvelt, A., Gottlieb, A. B., Vender, R., Korman, N. J., Thaçi, D., Zhao, Y., Gilloteau, I., Sherif, B., Williams, N., Guana, A., & Lebwohl, M. G. (2018). Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. J AM ACAD DERMATOL, 78(4), 741-748. https://doi.org/10.1016/j.jaad.2017.10.025

Vancouver

Puig L, Augustin M, Blauvelt A, Gottlieb AB, Vender R, Korman NJ et al. Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. J AM ACAD DERMATOL. 2018 Apr;78(4):741-748. https://doi.org/10.1016/j.jaad.2017.10.025

Bibtex

@article{05773014679b4dd5a853b7a7cb946103,
title = "Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study",
abstract = "BACKGROUND: Secukinumab has demonstrated greater sustained skin clearance than ustekinumab through week 52, greater improvement in symptoms and health-related quality of life, and comparable safety profile.OBJECTIVE: To assess the impact of secukinumab versus that of ustekinumab on complete relief from psoriasis-related symptoms, time to response in terms of health-related quality of life, and cumulative benefit among patients with moderate-to-severe plaque psoriasis.METHODS: Psoriasis-related pain, itching, and scaling and the Dermatology Life Quality Index (DLQI) score were compared between treatments on the basis of time to complete relief of symptoms and time to DLQI response in the CLEAR trial. Cumulative benefit over 52 weeks based on Psoriasis Area and Severity Index score, symptom relief, and DLQI response were evaluated by area under the curve analysis.RESULTS: Significantly more patients treated with secukinumab achieved complete relief of pain at weeks 16 and 52 (all P < .05). Complete relief of itching and scaling occurred significantly faster with secukinumab (median, 4 weeks faster for itching and 8 weeks faster for scaling [P < .001]). Response as measured by the DLQI was 4 weeks faster with secukinumab (P < .0001). Cumulative benefits were greater with secukinumab (all P < .05).LIMITATIONS: Analyses were post hoc.CONCLUSION: This patient-reported outcome analysis confirms greater and sustained benefits of secukinumab versus those of ustekinumab treatment on patients' lives.",
keywords = "Adult, Antibodies, Monoclonal, Dermatologic Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Psoriasis, Quality of Life, Severity of Illness Index, Time Factors, Ustekinumab, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial",
author = "Llu{\'i}s Puig and Matthias Augustin and Andrew Blauvelt and Gottlieb, {Alice B} and Ron Vender and Korman, {Neil J} and Diamant Tha{\c c}i and Yang Zhao and Isabelle Gilloteau and Bintu Sherif and Nicole Williams and Adriana Guana and Lebwohl, {Mark G}",
note = "Copyright {\textcopyright} 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.",
year = "2018",
month = apr,
doi = "10.1016/j.jaad.2017.10.025",
language = "English",
volume = "78",
pages = "741--748",
journal = "J AM ACAD DERMATOL",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "4",

}

RIS

TY - JOUR

T1 - Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study

AU - Puig, Lluís

AU - Augustin, Matthias

AU - Blauvelt, Andrew

AU - Gottlieb, Alice B

AU - Vender, Ron

AU - Korman, Neil J

AU - Thaçi, Diamant

AU - Zhao, Yang

AU - Gilloteau, Isabelle

AU - Sherif, Bintu

AU - Williams, Nicole

AU - Guana, Adriana

AU - Lebwohl, Mark G

N1 - Copyright © 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

PY - 2018/4

Y1 - 2018/4

N2 - BACKGROUND: Secukinumab has demonstrated greater sustained skin clearance than ustekinumab through week 52, greater improvement in symptoms and health-related quality of life, and comparable safety profile.OBJECTIVE: To assess the impact of secukinumab versus that of ustekinumab on complete relief from psoriasis-related symptoms, time to response in terms of health-related quality of life, and cumulative benefit among patients with moderate-to-severe plaque psoriasis.METHODS: Psoriasis-related pain, itching, and scaling and the Dermatology Life Quality Index (DLQI) score were compared between treatments on the basis of time to complete relief of symptoms and time to DLQI response in the CLEAR trial. Cumulative benefit over 52 weeks based on Psoriasis Area and Severity Index score, symptom relief, and DLQI response were evaluated by area under the curve analysis.RESULTS: Significantly more patients treated with secukinumab achieved complete relief of pain at weeks 16 and 52 (all P < .05). Complete relief of itching and scaling occurred significantly faster with secukinumab (median, 4 weeks faster for itching and 8 weeks faster for scaling [P < .001]). Response as measured by the DLQI was 4 weeks faster with secukinumab (P < .0001). Cumulative benefits were greater with secukinumab (all P < .05).LIMITATIONS: Analyses were post hoc.CONCLUSION: This patient-reported outcome analysis confirms greater and sustained benefits of secukinumab versus those of ustekinumab treatment on patients' lives.

AB - BACKGROUND: Secukinumab has demonstrated greater sustained skin clearance than ustekinumab through week 52, greater improvement in symptoms and health-related quality of life, and comparable safety profile.OBJECTIVE: To assess the impact of secukinumab versus that of ustekinumab on complete relief from psoriasis-related symptoms, time to response in terms of health-related quality of life, and cumulative benefit among patients with moderate-to-severe plaque psoriasis.METHODS: Psoriasis-related pain, itching, and scaling and the Dermatology Life Quality Index (DLQI) score were compared between treatments on the basis of time to complete relief of symptoms and time to DLQI response in the CLEAR trial. Cumulative benefit over 52 weeks based on Psoriasis Area and Severity Index score, symptom relief, and DLQI response were evaluated by area under the curve analysis.RESULTS: Significantly more patients treated with secukinumab achieved complete relief of pain at weeks 16 and 52 (all P < .05). Complete relief of itching and scaling occurred significantly faster with secukinumab (median, 4 weeks faster for itching and 8 weeks faster for scaling [P < .001]). Response as measured by the DLQI was 4 weeks faster with secukinumab (P < .0001). Cumulative benefits were greater with secukinumab (all P < .05).LIMITATIONS: Analyses were post hoc.CONCLUSION: This patient-reported outcome analysis confirms greater and sustained benefits of secukinumab versus those of ustekinumab treatment on patients' lives.

KW - Adult

KW - Antibodies, Monoclonal

KW - Dermatologic Agents

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Psoriasis

KW - Quality of Life

KW - Severity of Illness Index

KW - Time Factors

KW - Ustekinumab

KW - Comparative Study

KW - Journal Article

KW - Multicenter Study

KW - Randomized Controlled Trial

U2 - 10.1016/j.jaad.2017.10.025

DO - 10.1016/j.jaad.2017.10.025

M3 - SCORING: Journal article

C2 - 29066271

VL - 78

SP - 741

EP - 748

JO - J AM ACAD DERMATOL

JF - J AM ACAD DERMATOL

SN - 0190-9622

IS - 4

ER -